SLC5A2 and type 2 diabetes mellitus: Last, in an observational study of 26 subjects with T2DM treated for ~8-months with tofogliflozin (20 mg once daily), an SGLT2 inhibitor approved in Japan, an improvement in diastolic function as indicated by a lowering of the E/e′ was observed compared to 162 subjects with T2DM treated with other glucose-lowering medications (Otagaki et al., 2019).